A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 22 May 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Glioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 16 May 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
- 16 May 2017 Status changed from recruiting to discontinued.
- 09 Feb 2013 Planned number of patients changed from 90 to 92 as reported by European Clinical Trials Database.